WO2014004572A3 - Modulation of ube3a-ats expression - Google Patents
Modulation of ube3a-ats expression Download PDFInfo
- Publication number
- WO2014004572A3 WO2014004572A3 PCT/US2013/047701 US2013047701W WO2014004572A3 WO 2014004572 A3 WO2014004572 A3 WO 2014004572A3 US 2013047701 W US2013047701 W US 2013047701W WO 2014004572 A3 WO2014004572 A3 WO 2014004572A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ube3a
- modulation
- ats
- compounds
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015520410A JP6294876B2 (en) | 2012-06-25 | 2013-06-25 | Regulation of UBE3A-ATS expression |
ES13809694.6T ES2688831T3 (en) | 2012-06-25 | 2013-06-25 | UBE3A-ATS expression modulation |
EP20182895.1A EP3770258A1 (en) | 2012-06-25 | 2013-06-25 | Modulation of ube3a-ats expression |
EP18188705.0A EP3461895B1 (en) | 2012-06-25 | 2013-06-25 | Modulation of ube3a-ats expression |
US14/409,348 US9617539B2 (en) | 2012-06-25 | 2013-06-25 | Modulation of UBE3A-ATS expression |
CA2877905A CA2877905A1 (en) | 2012-06-25 | 2013-06-25 | Modulation of ube3a-ats expression |
PL18188705T PL3461895T3 (en) | 2012-06-25 | 2013-06-25 | Modulation of ube3a-ats expression |
DK13809694.6T DK2864479T3 (en) | 2012-06-25 | 2013-06-25 | MODULATION OF UBE3A-ATS EXPRESSION |
EP13809694.6A EP2864479B1 (en) | 2012-06-25 | 2013-06-25 | Modulation of ube3a-ats expression |
AU2013280474A AU2013280474B2 (en) | 2012-06-25 | 2013-06-25 | Modulation of UBE3A-ATS expression |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261664083P | 2012-06-25 | 2012-06-25 | |
US61/664,083 | 2012-06-25 | ||
US201261738959P | 2012-12-18 | 2012-12-18 | |
US61/738,959 | 2012-12-18 | ||
US201361750939P | 2013-01-10 | 2013-01-10 | |
US61/750,939 | 2013-01-10 | ||
US201361755617P | 2013-01-23 | 2013-01-23 | |
US61/755,617 | 2013-01-23 | ||
US201361772925P | 2013-03-05 | 2013-03-05 | |
US61/772,925 | 2013-03-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014004572A2 WO2014004572A2 (en) | 2014-01-03 |
WO2014004572A3 true WO2014004572A3 (en) | 2014-05-01 |
Family
ID=49784000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/047701 WO2014004572A2 (en) | 2012-06-25 | 2013-06-25 | Modulation of ube3a-ats expression |
Country Status (13)
Country | Link |
---|---|
US (1) | US9617539B2 (en) |
EP (3) | EP2864479B1 (en) |
JP (1) | JP6294876B2 (en) |
AU (1) | AU2013280474B2 (en) |
CA (1) | CA2877905A1 (en) |
DK (2) | DK3461895T3 (en) |
ES (2) | ES2688831T3 (en) |
HU (1) | HUE051698T2 (en) |
LT (1) | LT3461895T (en) |
PL (1) | PL3461895T3 (en) |
PT (1) | PT3461895T (en) |
SI (1) | SI3461895T1 (en) |
WO (1) | WO2014004572A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10400243B2 (en) | 2014-11-25 | 2019-09-03 | Ionis Pharmaceuticals, Inc. | Modulation of UBE3A-ATS expression |
PL3291843T3 (en) | 2015-05-07 | 2023-07-17 | University Of South Florida | Modified ube3a gene for a gene therapy approach for angelman syndrome |
ES2852998T3 (en) | 2015-11-12 | 2021-09-14 | Hoffmann La Roche | Oligonucleotides to induce expression of paternal UBE3A |
CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
EP3717646A4 (en) * | 2017-12-01 | 2021-12-01 | The Texas A&M University System | Angelman syndrome antisense treatment |
CN111770758A (en) * | 2018-02-27 | 2020-10-13 | 北卡罗来纳-查佩尔山大学 | Methods and compositions for treating Angelman syndrome |
CN112739353A (en) | 2018-06-14 | 2021-04-30 | 奥维德医疗公司 | Use of MIR-92A or MIR-145 for treating angeman syndrome |
KR20210065125A (en) * | 2018-09-21 | 2021-06-03 | 유니버시티 오브 코네티컷 | Compositions and methods for restoring paternal UBE3A gene expression in Angelman syndrome in humans |
CN113316722A (en) * | 2019-01-17 | 2021-08-27 | 豪夫迈·罗氏有限公司 | E3 ubiquitin ligase (UBE3A) protein targets |
AU2020253821A1 (en) * | 2019-03-29 | 2021-10-28 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating UBE3A-ATS |
KR20210158859A (en) * | 2019-05-22 | 2021-12-31 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | UBE3A gene and expression cassette and uses thereof |
US20220265607A1 (en) * | 2019-07-16 | 2022-08-25 | The University Of North Carolina At Chapel Hill | Methods and compositions for unsilencing imprinted genes |
EP4076471A4 (en) * | 2019-12-18 | 2023-12-27 | National University of Singapore | Method for treating angelman syndrome and related disorders |
WO2021222232A1 (en) * | 2020-04-28 | 2021-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome |
WO2022169861A2 (en) * | 2021-02-03 | 2022-08-11 | The Board Of Regents Of The University Of Texas System | Gene therapy for angelman syndrome |
WO2022236296A1 (en) * | 2021-05-05 | 2022-11-10 | The General Hospital Corporation | Therapy for treatment of prader-willi syndrome |
WO2023168000A1 (en) * | 2022-03-03 | 2023-09-07 | The Regents Of The University Of California | Compositions and methods for treatment of angelman syndrome |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001092582A1 (en) * | 2000-06-01 | 2001-12-06 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ube3a gene |
WO2011109398A2 (en) * | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
WO2012064806A2 (en) * | 2010-11-11 | 2012-05-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for unsilencing imprinted genes |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
FR2567892B1 (en) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
EP0942000B1 (en) | 1989-10-24 | 2004-06-23 | Isis Pharmaceuticals, Inc. | 2'-Modified oligonucleotides |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
ES2116977T3 (en) | 1990-05-11 | 1998-08-01 | Microprobe Corp | SOLID SUPPORTS FOR NUCLEIC ACID HYBRIDIZATION TESTS AND METHODS TO IMMOBILIZE OLIGONUCLEOTIDES IN A COVALENT WAY. |
US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
DE59208572D1 (en) | 1991-10-17 | 1997-07-10 | Ciba Geigy Ag | Bicyclic nucleosides, oligonucleotides, processes for their preparation and intermediates |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
FR2687679B1 (en) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | OLIGOTHIONUCLEOTIDES. |
EP0577558A2 (en) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates |
EP0673559A1 (en) | 1992-12-14 | 1995-09-27 | Honeywell Inc. | Motor system with individually controlled redundant windings |
CA2159631A1 (en) | 1993-03-30 | 1994-10-13 | Sanofi | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
US7875733B2 (en) | 2003-09-18 | 2011-01-25 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation |
JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
US6617162B2 (en) | 2001-12-18 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of estrogen receptor alpha expression |
IL135000A0 (en) | 1997-09-12 | 2001-05-20 | Exiqon As | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
US6043352A (en) | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
EP2363478B1 (en) | 1999-04-21 | 2019-07-24 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibiting the function of polynucleotide sequences |
KR100782896B1 (en) | 1999-05-04 | 2007-12-06 | 엑시콘 에이/에스 | L-Ribo-LNA analogues |
US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
US6300132B1 (en) | 1999-12-17 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Antisense inhibition of telomeric repeat binding factor 2 expression |
AU2698301A (en) | 1999-12-30 | 2001-07-16 | K.U. Leuven Research And Development | Cyclohexene nucleic acids |
US20030087855A1 (en) | 2001-09-13 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of protein kinase R expression |
WO2003004602A2 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
WO2004016754A2 (en) * | 2002-08-14 | 2004-02-26 | Pharmacia Corporation | ANTISENSE MODULATION OF Nav1.3 EXPRESSION |
CA2502649A1 (en) | 2002-10-18 | 2004-04-29 | Nucleonics Inc. | Double-stranded rna structures and constructs, and methods for generating and using the same |
WO2004044139A2 (en) | 2002-11-05 | 2004-05-27 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
JP2006507841A (en) | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | Functional and ultrafunctional siRNA |
US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
ES2382807T3 (en) | 2003-08-28 | 2012-06-13 | Takeshi Imanishi | New artificial nucleic acids of the N-O link type with cross-linking |
AU2005252662B2 (en) | 2004-06-03 | 2011-08-18 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
US20080261905A1 (en) | 2004-11-08 | 2008-10-23 | K.U. Leuven Research And Development | Modified Nucleosides for Rna Interference |
EP1764108A1 (en) * | 2005-09-14 | 2007-03-21 | Gunther Hartmann | Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides |
CN101437933B (en) | 2005-12-28 | 2013-11-06 | 斯克里普斯研究所 | Natural antisense and non-coding RNA transcripts as drug targets |
US7825099B2 (en) * | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
KR20130042043A (en) | 2006-01-27 | 2013-04-25 | 아이시스 파마수티컬즈 인코포레이티드 | 6-modified bicyclic nucleic acid analogs |
DK2066684T3 (en) | 2006-05-11 | 2012-10-22 | Isis Pharmaceuticals Inc | 5'-Modified Bicyclic Nucleic Acid Analogs |
WO2008101157A1 (en) | 2007-02-15 | 2008-08-21 | Isis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
WO2008150729A2 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
WO2009006478A2 (en) | 2007-07-05 | 2009-01-08 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
EP2265627A2 (en) | 2008-02-07 | 2010-12-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
US8604192B2 (en) | 2008-09-24 | 2013-12-10 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acids analogs |
WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
AT507215B1 (en) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | WEAR-RESISTANT MATERIAL |
US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
CA2782373C (en) | 2009-12-23 | 2019-03-26 | Opko Curna, Llc | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
EP2601204B1 (en) | 2010-04-28 | 2016-09-07 | Ionis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
CN103068982B (en) | 2010-07-14 | 2017-06-09 | 库尔纳公司 | DLG relevant diseases are treated by suppressing the natural antisense transcript of the big homologue of plate-like (DLG) |
WO2012012467A2 (en) | 2010-07-19 | 2012-01-26 | Isis Pharmaceuticals, Inc. | Modulation of nuclear-retained rna |
WO2013006857A1 (en) | 2011-07-07 | 2013-01-10 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2013
- 2013-06-25 ES ES13809694.6T patent/ES2688831T3/en active Active
- 2013-06-25 EP EP13809694.6A patent/EP2864479B1/en active Active
- 2013-06-25 JP JP2015520410A patent/JP6294876B2/en active Active
- 2013-06-25 HU HUE18188705A patent/HUE051698T2/en unknown
- 2013-06-25 EP EP20182895.1A patent/EP3770258A1/en active Pending
- 2013-06-25 CA CA2877905A patent/CA2877905A1/en active Pending
- 2013-06-25 DK DK18188705.0T patent/DK3461895T3/en active
- 2013-06-25 PT PT181887050T patent/PT3461895T/en unknown
- 2013-06-25 EP EP18188705.0A patent/EP3461895B1/en not_active Revoked
- 2013-06-25 SI SI201331770T patent/SI3461895T1/en unknown
- 2013-06-25 DK DK13809694.6T patent/DK2864479T3/en active
- 2013-06-25 AU AU2013280474A patent/AU2013280474B2/en active Active
- 2013-06-25 ES ES18188705T patent/ES2809199T3/en active Active
- 2013-06-25 WO PCT/US2013/047701 patent/WO2014004572A2/en active Application Filing
- 2013-06-25 LT LTEP18188705.0T patent/LT3461895T/en unknown
- 2013-06-25 US US14/409,348 patent/US9617539B2/en active Active
- 2013-06-25 PL PL18188705T patent/PL3461895T3/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001092582A1 (en) * | 2000-06-01 | 2001-12-06 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ube3a gene |
WO2011109398A2 (en) * | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
WO2012064806A2 (en) * | 2010-11-11 | 2012-05-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for unsilencing imprinted genes |
Non-Patent Citations (3)
Title |
---|
DATABASE PMID [online] XP055183568, Database accession no. 11726556 * |
PLAGGE, A.: "Non-coding RNAs at the Gnas and Snrpn-Ube3a Imprinted Gene Loci and their Involvement in Hereditary Disorders.", FRONTIERS IN GENETICS., vol. 3, no. 264, November 2012 (2012-11-01), pages 1 - 6, XP055183571 * |
RUNTE, M ET AL.: "The IC-SNURF-SNRPN Transcript Serves as a Host for Multiple Small Nucleolar RNA Species and as an Antisense RNA for UBE3A.", HUMAN MOLECULAR GENETICS, vol. 10, no. 23, 2001, pages 2687 - 2700, XP055183568 * |
Also Published As
Publication number | Publication date |
---|---|
AU2013280474B2 (en) | 2019-01-03 |
DK2864479T3 (en) | 2018-10-22 |
EP3770258A1 (en) | 2021-01-27 |
US9617539B2 (en) | 2017-04-11 |
EP2864479A4 (en) | 2016-06-08 |
JP2015529635A (en) | 2015-10-08 |
CA2877905A1 (en) | 2014-01-03 |
WO2014004572A2 (en) | 2014-01-03 |
US20150191723A1 (en) | 2015-07-09 |
ES2688831T3 (en) | 2018-11-07 |
PT3461895T (en) | 2020-09-08 |
EP3461895A1 (en) | 2019-04-03 |
ES2809199T3 (en) | 2021-03-03 |
DK3461895T3 (en) | 2020-07-20 |
EP2864479B1 (en) | 2018-08-15 |
SI3461895T1 (en) | 2020-10-30 |
HUE051698T2 (en) | 2021-03-29 |
AU2013280474A1 (en) | 2015-01-22 |
EP2864479A2 (en) | 2015-04-29 |
EP3461895B1 (en) | 2020-07-01 |
PL3461895T3 (en) | 2021-01-11 |
LT3461895T (en) | 2020-09-10 |
JP6294876B2 (en) | 2018-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014004572A3 (en) | Modulation of ube3a-ats expression | |
WO2012177810A3 (en) | Improved electric power supply and related methods | |
IL233503B (en) | Isocitrate dehydrogenase inhibitors, compositions comprising same and uses thereof | |
EP2558478A4 (en) | 5-position modified pyrimidines and their use | |
EP3460064B8 (en) | Efficient protein expression in vivo using modified rna (mod-rna) | |
EP3033325A4 (en) | Compositions and methods for delivering messenger rna | |
WO2012058211A3 (en) | Quinazoline derivatives, compositions, and uses related thereto | |
IN2014DN08481A (en) | ||
WO2011159770A3 (en) | Methods and compositions for promoting hair growth | |
ZA201304940B (en) | Granzyme b inhibitor compositions, methods and uses for promoting wound healing | |
EP2789245A4 (en) | Emulsion composition, and composition containing same | |
WO2012054862A9 (en) | Agents, compositions, and methods for treating pruritis and related skin conditions | |
EP2548022A4 (en) | Multiphase microarrays and uses thereof | |
EP2852588B8 (en) | Hydantoin derivatives as kv3 inhibitors | |
WO2013063391A3 (en) | Transgenic animals and methods of use | |
GB2489187B (en) | Compositions, methods and related uses for cleaving modified DNA | |
EP2652524A4 (en) | Dosimetry system, methods, and components | |
EP2555834A4 (en) | Flippers, boots, systems including same, and methods of using same | |
WO2012109238A3 (en) | Methods for increasing immune responses using agents that directly bind to and activate ire-1 | |
ZA201406381B (en) | Levoisovalerylspiramycin i,ii,iii,and preparations,preparations methods and uses thereof | |
MX359181B (en) | Collagen hydrolysate and use thereof. | |
WO2013029011A3 (en) | Methods and compositions comprising a c-terminal bax peptide | |
EP2683076A4 (en) | Virtual admittance controller based on static power converters | |
WO2012030854A3 (en) | Compositions and methods for modulating emt and uses thereof | |
EP2569327A4 (en) | Eif4e binding peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13809694 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14409348 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2877905 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015520410 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013280474 Country of ref document: AU Date of ref document: 20130625 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13809694 Country of ref document: EP Kind code of ref document: A2 |